Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 1
2018 1
2019 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
The emerging role of electronic medical records in pharmacogenomics.
Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G. Wilke RA, et al. Clin Pharmacol Ther. 2011 Mar;89(3):379-86. doi: 10.1038/clpt.2010.260. Epub 2011 Jan 19. Clin Pharmacol Ther. 2011. PMID: 21248726 Free PMC article. Review.
Health-care information technology and genotyping technology are both advancing rapidly, creating new opportunities for medical and scientific discovery. ...By linking biological material to comprehensive medical records, large multi-institutional biob
Health-care information technology and genotyping technology are both advancing rapidly, creating new opportunities for medical
Leveraging electronic health records to assess the role of ADRB2 single nucleotide polymorphisms in predicting exacerbation frequency in asthma patients.
Sood N, Connolly JJ, Mentch FD, Vazquez L, Sleiman PMA, Hysinger EB, Hakonarson H; eMERGE Outcomes Workgroup. Sood N, et al. Pharmacogenet Genomics. 2018 Nov;28(11):256-259. doi: 10.1097/FPC.0000000000000355. Pharmacogenet Genomics. 2018. PMID: 30334910 Free PMC article.
These correspond to nonsynonymous single nucleotide polymorphisms at positions 16 [arginine to glycine (Arg16Gly); rs1042713] and 27 [glutamic acid to glutamine (Glu27Gln); rs1042714], which are relatively common (minor allele frequencies 40-50%), and have been well characterized …
These correspond to nonsynonymous single nucleotide polymorphisms at positions 16 [arginine to glycine (Arg16Gly); rs1042713] and 27 [glutam …
An assessment of patient perspectives on pharmacogenomics educational materials.
Asiedu GB, Finney Rutten LJ, Agunwamba A, Bielinski SJ, St Sauver JL, Olson JE, Rohrer Vitek CR. Asiedu GB, et al. Pharmacogenomics. 2020 Apr;21(5):347-358. doi: 10.2217/pgs-2019-0175. Epub 2020 Apr 15. Pharmacogenomics. 2020. PMID: 32292118 Free PMC article.
Aim: Pharmacogenomics (PGx) holds potential to improve patient treatment; yet, effective patient educational materials are limited. ...
Aim: Pharmacogenomics (PGx) holds potential to improve patient treatment; yet, effective patient educational materials are limited. . …
Role of Pharmacovigilance in India: An overview.
Suke SG, Kosta P, Negi H. Suke SG, et al. Online J Public Health Inform. 2015 Jul 1;7(2):e223. doi: 10.5210/ojphi.v7i2.5595. eCollection 2015. Online J Public Health Inform. 2015. PMID: 26392851 Free PMC article.
PV is concerns with the detection, assessment, understanding and prevention of ADRs. Pharmacogenetics and pharmacogenomics are an indispensable part of the clinical research. ...The research focus is shifting toward the use of data generated from platforms outside t …
PV is concerns with the detection, assessment, understanding and prevention of ADRs. Pharmacogenetics and pharmacogenomics are …
Drug-resistant epilepsy classified by a phenotyping algorithm associates with NTRK2.
Almoguera B, McGinnis E, Abrams D, Vazquez L, Cederquist A, Sleiman PM, Dlugos D, Hakonarson H; eMERGE Epilepsy Research Group. Almoguera B, et al. Acta Neurol Scand. 2019 Sep;140(3):169-176. doi: 10.1111/ane.13115. Epub 2019 Jun 20. Acta Neurol Scand. 2019. PMID: 31070779
OBJECTIVE: Up to 40% of patients with epilepsy become drug resistant (DRE). Genetic factors are likely to play a role. While efforts have focused on the transporter and target hypotheses, neither of them fully explains the pan-pharmacoresistance seen in DRE. MATERIALS AND …
OBJECTIVE: Up to 40% of patients with epilepsy become drug resistant (DRE). Genetic factors are likely to play a role. While efforts …
Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology.
Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM. Bernsen EC, et al. Front Pharmacol. 2020 Aug 5;11:1184. doi: 10.3389/fphar.2020.01184. eCollection 2020. Front Pharmacol. 2020. PMID: 32848787 Free PMC article. Review.
An explanation for the diversity in response to chemotherapy is genetic variation, leading to differences in expression and activity of metabolizing and transport enzymes as well as drug targets. Pharmacogenetic testing has emerged as a promising tool to predict and limit …
An explanation for the diversity in response to chemotherapy is genetic variation, leading to differences in expression and activity of meta …